^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lung Adenocarcinoma
    Drug:Alecensa (alectinib) (ALK inhibitor) +
    Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report

    Published date:
    10/01/2021
    Excerpt:
    Here, we report a case of ALK-positive lung adenocarcinoma with meningeal carcinomatosis in which lorlatinib was used after resistance to alectinib and brigatinib….At 8 months from the initiation of lorlatinib, the patient remained well without disease progression.
    DOI:
    10.1097/MD.0000000000027385